|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Ariad_Pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Glyco_Mimetics,_Inc.
Mirati acquired the rights to Adagrasib.
|
|
gptkbp:ceo
|
gptkb:Charles_M._Baum
|
|
gptkbp:clinical_trial
|
Phase 3 trials
ongoing clinical trials
combination therapies
Phase 1 trials
Phase 2 trials
monotherapy studies
|
|
gptkbp:collaborations
|
gptkb:Johns_Hopkins_University
gptkb:University_of_California,_San_Diego
collaboration with academic institutions
|
|
gptkbp:committee
|
composed of industry experts
|
|
gptkbp:employees
|
approximately 200
|
|
gptkbp:financial_products
|
gptkb:Company
|
|
gptkbp:focus
|
cancer therapeutics
|
|
gptkbp:focus_area
|
targeted therapies
|
|
gptkbp:founded
|
gptkb:2010
|
|
gptkbp:headquarters
|
gptkb:San_Diego,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mirati Therapeutics, Inc.
|
|
gptkbp:investment
|
$100 million funding round
|
|
gptkbp:language_of_instruction
|
multiple drug candidates
|
|
gptkbp:market_cap
|
approximately $1 billion
|
|
gptkbp:mission
|
transform the lives of patients with cancer.
|
|
gptkbp:partnership
|
gptkb:temple
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Eli_Lilly_and_Company
gptkb:Novartis
|
|
gptkbp:products
|
gptkb:Adagrasib
gptkb:Mirati's_KRAS_inhibitor
Krazati
|
|
gptkbp:receives_funding_from
|
grants and investments
|
|
gptkbp:regulatory_compliance
|
FDA approval for Adagrasib
FDA approval for Krazati
|
|
gptkbp:research_areas
|
oncology
rare diseases
hematology
immuno-oncology
genetic drivers of cancer
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
solid tumors
oncogenic drivers
|
|
gptkbp:symbol
|
MRTX
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.mirati.com
|